Latest Commercialization News

Elixir Energy has secured an independent certification for a maiden contingent resource of 245 billion cubic feet of deep dry coal gas, lifting its Grandis Gas Project’s recoverable resources by 17%. This milestone underscores the significant untapped potential within the Taroom Trough’s deep coal formations.

St George Mining has inked a pivotal Memorandum of Understanding with steel giant Liaoning Fangda Group, setting the stage for collaborative development and offtake of its high-grade Araxá niobium-REE project in Brazil.

5E Advanced Materials has announced a $30 million funding package alongside a significant restructuring of its convertible notes, aiming to strengthen its balance sheet and advance toward a Final Investment Decision.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Megado Minerals has secured an agreement to acquire an 80% stake in a significant copper project in Spain and entered a strategic exploration deal for rare earths in the US, positioning itself at the forefront of critical minerals supply.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

First Graphene Limited has responded to an ASX price query, attributing its recent share price and volume surge to increased buying activity in Germany linked to prior commercial announcements, while reaffirming full compliance with ASX disclosure rules.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.

ADX Energy has suspended testing at its Welchau-1 gas well in Upper Austria following a landmark Austrian Constitutional Court ruling that repealed a legal provision preventing environmental objections from halting operations. This development introduces regulatory uncertainty amid ongoing evaluation of the well’s potential.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

Foresta Group Holdings secures a significant regulatory boost as its Kawerau renewable energy project is included in New Zealand’s Fast-Track Approvals Act 2024, expediting the path to construction and operation.